Tommy (on behalf of Salveen Richter)'s questions to Alnylam Pharmaceuticals Inc (ALNY) leadership • Q1 2025
Question
Tommy, on for Salveen Richter, asked for confirmation of the early launch metrics, such as the number of health systems with formulary access. He also inquired if more standardized guidelines are emerging for identifying patients who are progressing on stabilizer therapies.
Answer
CCO Tolga Tanguler confirmed the metrics regarding health system access. Chief Medical Officer Pushkal Garg addressed the second question, stating that cardiologists are already well-equipped to identify heart failure progression using standard clinical symptoms, imaging, and biomarkers. He emphasized that AMVUTTRA showed benefit across all these measures in the HELIOS-B study, which is compelling for physicians.